cymabay
announces
study
evaluate
potential
agonists
prevent
hypoglycemia
type
diabetes
newark
globe
newswire
cymabay
therapeutics
nasdaq
cbay
biopharmaceutical
company
focused
developing
therapies
liver
chronic
diseases
high
unmet
need
today
announced
provide
proprietary
investigational
agonist
assist
regulatory
filings
clinical
study
conducted
tri
cymabay
wholly
owns
retains
rights
objective
study
determine
agonists
potential
prevent
hypoglycemia
people
living
trial
funded
nearly
million
grant
leona
harry
helmsley
charitable
trust
helmsley
glucagon
hormone
secreted
pancreas
naturally
reverses
hypoglycemia
signaling
body
release
stored
glucose
process
defective
individuals
diabetes
left
uncorrected
hypoglycemia
lead
unconsciousness
death
preventing
episodes
hypoglycemia
persons
diabetes
unmet
medical
need
according
global
hat
study
people
individuals
reported
hypoglycemia
rate
severe
hypoglycemia
requiring
assistance
another
person
approximately
events
per
recent
preclinical
studies
agonists
shown
enhance
glucagon
secretion
response
low
glucose
levels
able
prevent
hypoglycemia
animal
models
translate
findings
tri
orlando
fl
test
cymabay
phase
study
determine
whether
drug
enhance
glucagon
secretion
hypoglycemia
subjects
sujal
shah
president
ceo
cymabay
stated
grateful
able
contribute
effort
evaluate
agonist
potential
treat
individuals
risk
hypoglycemia
one
challenging
potentially
life
threatening
complications
insulin
therapy
richard
pratley
md
samuel
crockett
chair
diabetes
research
diabetes
program
head
tri
said
hypoglycemia
common
among
persons
barrier
achieving
optimal
glycemic
control
many
patients
unique
opportunity
explore
whether
class
drugs
address
key
unmet
need
management
ben
williams
phd
program
officer
helmsley
program
stated
preventing
hypoglycemia
major
focus
helmsley
program
happy
support
efforts
show
whether
class
drug
might
help
improve
lives
people
study
activities
underway
tri
cymabay
provide
updates
study
design
objectives
results
throughout
study
daily
oral
agonist
previously
studied
type
diabetes
favorable
profile
toxicology
studies
two
species
six
months
duration
appeared
safe
well
tolerated
five
previous
clinical
studies
dosing
subjects
duration
days
cymabay
fully
owns
rights
g
receptor
expressed
pancreatic
islets
gastrointestinal
tract
studies
conducted
cymabay
others
show
agonists
stimulate
insulin
secretion
release
incretin
hormones
thus
may
preserve
beta
cell
health
previously
evaluated
treating
type
diabetes
mellitus
due
action
stimulate
insulin
secretion
glucose
dependent
manner
hypoglycemia
diabetes
hypoglycemia
diabetes
significant
limiting
factor
achieving
desired
glucose
control
cause
significant
morbidity
common
unpredictable
dangerous
side
effect
treatment
especially
diabetics
using
insulin
advanced
type
diabetics
compromised
physiological
defenses
falling
plasma
glucose
concentrations
result
pathophysiology
defective
glucose
counter
regulation
mechanisms
normally
prevent
rapidly
correct
hypoglycemia
duration
disease
progresses
glucose
counterregulatory
mechanisms
opposing
hypoglycemia
diabetics
becomes
impaired
hypoglycemia
perceived
risk
obstacle
achieving
glucose
control
treatment
goals
many
patients
fearful
dangerous
hypoglycemic
episodes
become
conservative
use
insulin
preventing
achievement
adequate
glucose
control
currently
therapies
restoring
natural
physiologic
response
changes
glucose
levels
order
prevent
least
blunt
hypoglycemic
episodes
cymabay
cymabay
therapeutics
biopharmaceutical
company
focused
developing
therapies
liver
chronic
diseases
high
unmet
medical
need
cautionary
statements
statements
press
release
regarding
expected
potential
future
events
results
including
potential
benefits
well
plans
evaluate
forward
looking
statements
subject
risks
uncertainties
actual
results
timing
events
could
differ
materially
anticipated
statements
result
risks
uncertainties
include
without
limitation
risks
related
success
cost
timing
product
development
activities
including
clinical
trials
additional
risks
relating
cymabay
contained
cymabay
filings
securities
exchange
commission
including
without
limitation
recent
annual
report
form
documents
subsequently
filed
furnished
securities
exchange
commission
cymabay
disclaims
obligation
update
statements
except
required
law
additional
information
cymabay
visit
public
relations
contact
glenn
silver
partners
investor
relations
contact
hans
vitzthum
lifesci
advisors
llc
hans
